Jump to content

KAHR Announces First Patient Dosed in Phase 1/2 Clinical Trial of DSP107, Bi-Functional CD47x41BB Candidate for the Treatment of Solid Tumors

In The News

Recommended Posts

Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.


  • Create New...